Literature DB >> 2975551

The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption.

F H Ziel1, M B Davidson, M D Harris, C S Rosenberg.   

Abstract

Eight normal subjects were studied twice for 360 min after the subcutaneous injection of unmodified insulin (0.15 U kg-1) during euglycaemic clamps. Insulin absorption was assessed by both the area under the insulin-time curve above baseline (AUC) and time course of absorption (time to 25% and 50% of total AUC). Insulin action was measured as the amount of glucose infused. The maximal serum insulin concentration was 0.27 +/- 0.02 (+/- SE) nmol l-1 at 112 +/- 10 min. Fifty percent of total glucose infused occurred at 218 +/- 7 min. The maximal glucose infusion rate was 5.11 +/- 0.70 mg kg-1 min-1 and occurred at 256 +/- 12 min. Intrasubject coefficients of variation (CV) for total insulin AUC (11.2%), time to 25% of maximum AUC (12.1%) and time to 50% of maximum AUC (10.2%) were considerably lower than that for total insulin action (22.6%). Total insulin AUC did not correlate with total glucose utilization (r = 0.06, NS). We conclude that when glucose concentrations are maintained by euglycaemic clamps the peak of unmodified insulin action is later and the duration longer than traditionally recognized, insulin AUC does not predict insulin action, and the higher variability of insulin action compared with the indices of absorption suggests that day-to-day changes in tissue insulin sensitivity contribute more to the variability in insulin action than changes in absorption.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2975551     DOI: 10.1111/j.1464-5491.1988.tb01076.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

1.  Insulin depot formation in subcutaneoue tissue.

Authors:  James P Leuenberger Jockel; Philipp Roebrock; Oliver A Shergold
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

Review 2.  Human insulin.

Authors:  J Pickup
Journal:  BMJ       Date:  1989-10-21

3.  A Conversation on an Effective, Straightforward, Quantitative Approach to the Outpatient Use of Insulin.

Authors:  Mayer B Davidson
Journal:  Diabetes Spectr       Date:  2022-01-10

4.  Dynamic insulin on board: incorporation of circadian insulin sensitivity variation.

Authors:  Chiara Toffanin; Howard Zisser; Francis J Doyle; Eyal Dassau
Journal:  J Diabetes Sci Technol       Date:  2013-07-01

5.  Unblinded CGM Should Replace Blinded CGM in the Clinical Management of Diabetes.

Authors:  David Ahn; Jeremy Pettus; Steven Edelman
Journal:  J Diabetes Sci Technol       Date:  2016-05-03

6.  Self-mixed/split insulin regimen: a serious omission in the ADA/EASD position statement.

Authors:  Mayer B Davidson
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

7.  Insulin analogs--is there a compelling case to use them? No!

Authors:  Mayer B Davidson
Journal:  Diabetes Care       Date:  2014-06       Impact factor: 19.112

8.  Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.

Authors:  Tim Heise; Kirstine Stender-Petersen; Ulrike Hövelmann; Jacob Bonde Jacobsen; Leszek Nosek; Eric Zijlstra; Hanne Haahr
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

Review 9.  Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability.

Authors:  A K J Gradel; T Porsgaard; J Lykkesfeldt; T Seested; S Gram-Nielsen; N R Kristensen; H H F Refsgaard
Journal:  J Diabetes Res       Date:  2018-07-04       Impact factor: 4.011

10.  Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.

Authors:  Leona Plum-Mörschel; Gursharan Singh; Sundara Moorthi Nainar Murugesan; Ashwani Marwah; Jayanti Panda; Subramanian Loganathan; Sandeep N Athalye
Journal:  Diabetes Obes Metab       Date:  2022-01-28       Impact factor: 6.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.